Barclays
EMMA

Barclays’s Emmaus Life Sciences, Inc. Common Stock EMMA Stock Holding History

Barclays’s Portfolio EMMA Stock Details EMMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2
Closed – – 7496
2018
Q1 		$0 Buy
+2
New +$32 ﹤0.01% 7520

Other funds holding EMMA

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HFM
Hartford Financial Management Hartford, Connecticut $392M AUM 21.9% 1-Year Est. Return

Barclays's EMMA Position: Q2 2018 in Review

Barclays sold out of Emmaus Life Sciences, Inc. Common Stock (EMMA) in Q2 2018, closing a stake of 2 shares.

Barclays first reported a position in EMMA in Q1 2018 and held it in 1 quarter. The position peaked at $0 in Q1 2018. 12 funds tracked by Wall St. Rank hold EMMA as of Q2 2018.

  • Barclays reported no remaining Emmaus Life Sciences, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Barclays sold 2 Emmaus Life Sciences, Inc. Common Stock shares in Q2 2018.
  • Barclays first reported a position in Emmaus Life Sciences, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • Barclays's Emmaus Life Sciences, Inc. Common Stock position peaked at $0 in Q1 2018.
  • 12 funds tracked by Wall St. Rank held Emmaus Life Sciences, Inc. Common Stock as of Q2 2018.

Based on Barclays's 13F filing for Q2 2018, filed 14 Aug 2018.